ClinicalTrials.gg
RecruitingNCT05985850THC-MMTUpdated Feb 17, 2025

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

A Phase 2 interventional study of Aurora 1:1 Drops (Indica) and Placebo in Opioid Use Disorder, Methadone and Cannabis, sponsored by BC Centre on Substance Use. Recruiting at 1 site in Canada. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by BC Centre on Substance Use · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Opioid-Related Disorders with a site in Canada — 11 open to participants now, 12 under way, 1 of them phase 3. Opioid-Related Disorders · Canada.

Planned enrollment
25th of 32
24 · median 51
Started
2024
with 3 others
Phase 2
4 of 36
4 open now
Primary completion
2026-03
later than 2 of 11 live
Registered
28th of 36
by date
Lead sponsor
2 of 36
BC Centre on Substance Use

Among the 36 studies in Opioid-Related Disorders with a site in Canada, this one is the 25th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 28th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

11 of the 36 studies in Opioid-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Opioid-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.

Read the detailed description

This is a single-site, two-phase pilot clinical trial evaluating the safety and feasibility of administering a balanced 1:1 ratio of THC:CBD cannabis oil alongside methadone-based opioid agonist therapy (OAT) in a community setting.

Phase 1 is a 12-week, double-blind, randomized controlled study involving 24 eligible participants with opioid use disorder (OUD) who recently initiated or re-initiated methadone-based OAT. Participants will be randomly assigned to receive either balanced THC:CBD cannabis oil or placebo oil. All participants will receive OUD clinical care, including OAT management, independent of research visits.

After the 12-week blinded treatment period (Phase 1), eligible participants will be invited to Phase 2, a 12-week open-label treatment extension study with all participants receiving balanced THC:CBD cannabis oil. Follow-up research visits will occur every two weeks from the start of open-label treatment.

03

Conditions studied

  • Opioid Use Disorder
  • Methadone
  • Cannabis
  • Fentanyl

Keywords

  • addiction
  • Opioid Use Disorder
  • Cannabis
  • Harm Reduction
  • Opioid
  • Pain
  • Quality of Life
  • Cannabidiol
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Individuals of at least 25 years of age or older;
  2. Diagnosed with OUD as per criteria;
  3. Initiated or re-initiated methadone-based OAT within the past 30 days prior to study entry;
  4. Cannabis-use experienced, defined as having used any amount of cannabis in the six months prior to the screening visit;
  5. Willing to only use study-provided cannabis as directed by study protocol, including abstention from non-study cannabis and cannabinoids;
  6. Agree to keep all study medication stored in a secure location and not to share/distribute study medication to any other individual;
  7. If assigned female sex at birth:

    1. Be of non-, defined as (i) (12 months of spontaneous amenorrhea and over 45 years of age); or (ii) documented surgical sterilization (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or
    2. If of childbearing potential, be willing to use an acceptable method of throughout the study and have a negative pregnancy test at screening;
  8. Ability to understand and comply with study protocol procedures and to provide written .

Inclusion criteria for Phase 2

In addition to meeting all eligibility criteria outlined in Phase 1, participants will be eligible for Phase 2 provided they meet ALL the following criteria at Week 12:

  1. Participants who have not experienced a study medication-related serious adverse event during Phase 1;
  2. Participants who have not been lost to follow-up during Phase 1.

Exclusion Criteria:

  1. Any disabling, severe, or unstable medical or psychiatric condition that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent, as assessed by medical and psychiatric history, physical examination, vital signs, and/or laboratory tests;
  2. Any severe or unstable co-morbid substance use disorder (e.g., delirium tremens, acute alcohol intoxication) that, in the opinion of the study physician, precludes safe participation in the study;
  3. Currently pregnant or breastfeeding, or planning to become pregnant;
  4. Known or suspected allergy or to cannabinoids;
  5. History of respiratory disease, severe cardiovascular, cerebrovascular, renal or liver disease;
  6. Current or historic cannabis use disorder;
  7. Taking warfarin, clopidogrel, clobazam, theophylline, clozapine and olanzapine medications as they may interact with cannabinoids in a manner if they cannot be switched to a different medication;
  8. Any personal or family history (first degree relative) of primary psychotic disorders (i.e., schizophrenia, schizoaffective disorder) as per DSM-5 criteria;
  9. Unable to abstain from driving any vehicle or operating machinery for at least 10 hours after taking the study medication. In cases where impairment persists beyond the initial 10-hour period, participants must continue to adhere to these restrictions until the impairment resolves;
  10. Actively participating in other interventional clinical trial(s);
  11. Incarcerated, pending legal action or other reasons that might prevent completion of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Aurora 1:1 Drops (Indica)

    Aurora 1:1 Drops (Indica) Balanced 1:1 ratio of THC and CBD packaged in a 30 mL bottle: THC: 16.8 mg/g (+/- 15%) CBD: 16.8 mg/g (+/- 15%) Induction and dosing will be ad libitum and sublingually self-administered. Initial dose will be 5 mg (equivalent to 0.25 mL)/day and participants will be able to titrate in increments of 2.5mg (0.125 mL)/day up to a maximum of 40 mg (2 mL)/day, in consultation with a study physician.

    Drug: Aurora 1:1 Drops (Indica)

  • Placebo comparator
    Placebo

    Formulated using the same medium chain triglyceride (MCT) oil as Aurora 1:1 Drops (Indica) Induction and dosing will be ad libitum and sublingually self-administered. Initial dose will be 5 mg (equivalent to 0.25 mL)/day and participants will be able to titrate in increments of 2.5mg (0.125 mL)/day up to a maximum of 40 mg (2 mL)/day, in consultation with a study physician.

    Drug: Placebo

Interventions

  • DrugAurora 1:1 Drops (Indica)

    Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.

  • DrugPlacebo

    Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The safety will be evaluated by monitoring and gathering information on physical exam, vital signs, pregnancy testing, adverse events (AE) and serious adverse events (SAE), from the screening visit up to the End of Treatment (EOT)/Early Termination visit. AEs and SAEs will be monitored and recorded throughout the study duration. The proportion of participants who experience AEs or SAEs will be assessed by study arm.

    Time frame: 28 weeks

  2. Risk of Treatment Contamination

    The proportion of participants using non-study cannabis in the control arm, and proportion of days in Phase 1 where non-study cannabis was used. Self-report of non-study cannabis use will be collected using the Timeline Follow Back (TLFB).

    Time frame: 24 weeks

  3. Participants' adherence to treatment

    The degree of compliance with the recommended treatment plan, including study drug dosage and administration. This measures how well participants are able to stick to the prescribed treatment regimen and whether or not they are able to complete the full course of treatment. This will be assessed through a self-reported measure, such as study drug diary or treatment logs.

    Time frame: 24 weeks

  4. Acceptability

    Participant satisfaction with the assigned treatment will be assessed through administration of the Medical Safety Questionnaire (MSQ) every 4 weeks during treatment phase The MSQ is a participant-completed questionnaire that evaluates participant satisfaction with study treatment on a 7-point Likert scale.

    Time frame: 24 weeks

  5. Blinding effectiveness

    The blinding success questionnaire will be used to evaluate the participants' awareness of their assigned treatment.

    Time frame: 24 weeks

  6. Adequacy of Dose

    Patient satisfaction with dose level assessed through the adequacy of dose questionnaire and regular consultations

    Time frame: 24 weeks

Secondary outcomes

  1. The number of potential participants referred to the study

    Time frame: 24 weeks

  2. The screening failure rates

    Time frame: 24 weeks

  3. The monthly enrolment rates

    Time frame: 24 weeks

  4. The proportion of eligible participants who are willing to be randomized, willing to initiate the intervention and willing to complete 12-week assessments by study arm

    Time frame: 24 weeks

  5. The proportion of scheduled study visits completed by study arm

    Time frame: 24 weeks

Other outcomes

  1. Retention in OAT

    Retention in OAT will be measured by the proportion of participants on OAT at W12 and at W24, defined as having both a) an active OAT prescription at week 12/24, and b) a positive UDT result for the prescribed OAT at week 12/24.

    Time frame: 24 weeks

  2. Illicit opioid use

    Suppression of illicit opioid use will be measured as the percentage of opioid-free weeks during W1-12, using a combination of Urine Drug Test (UDT) results and self-reported illicit opioid use assessed by the TLFB.

    Time frame: 24 weeks

  3. Pain Intensity

    The severity of pain will be assessed by the validated scale within the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Profile v2.1 (PROPr): the PROMIS Pain Intensity item.

    Time frame: 24 weeks

  4. Pain Interference

    The impact of pain on its impact on functioning will be assessed the validated scale within the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Profile v2.1 (PROPr): PROMIS SF v1.0 - Pain Interference 4a scale.

    Time frame: 24 weeks

  5. Anxiety

    Anxiety symptoms will be assessed by the validated short scale within the PROMIS 29+2 Profile v2.1 (PROPr): the PROMIS SF v1.0 - Anxiety 4a

    Time frame: 24 weeks

  6. Depression

    Depressive symptoms will be assessed by the validated short scale within the PROMIS 29+2 Profile v2.1 (PROPr): the PROMIS SF v1.0 - Depression 4a.

    Time frame: 24 weeks

  7. Changes in health-related quality of life

    Changes in health-related quality of life (HRQoL) between screening and the end of treatment will be measured by the PROMIS 29+2 Profile v2.1 (PROPr).

    Time frame: 24 weeks

  8. Changes in substance-use related problems

    The Addiction Severity Index (ASI) Self-Report form will be used to assess changes in substance-use related problems between Baseline (W0) prior to the start of treatment administration, Treatment Visit at W12 and EOT (W24)/Early Termination.

    Time frame: 24 weeks

  9. Opioid Craving

    Opioid craving over time will be measured using a 100-mm visual analog scale (VAS), with 11 lines labeled from left to right with the numbers "0" to "10", and word anchors at each end representing the extremes, where "0=no craving" and "100 mm=most intense craving".

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Rapid Access Addiction Clinic (RAAC), St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2026, 22 months after the start.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 22 months is below that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 14, 2023
StartActual
May 23, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2027
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05985850
Lead sponsor
BC Centre on Substance Use
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
M. Eugenia Socias (Assistant Professor, Department of Medicine, UBC; Research Scientist, BCCSU, BC Centre on Substance Use) — Principal investigator
First posted
Aug 14, 2023
Start date
May 23, 2024
Primary completion
Mar 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 17, 2025

Study contacts

Josie Kanu, BSc
Contact
josie.kanu@bccsu.ubc.ca
6045001102
M Eugenia Socias, MD, MSc.
principal investigator · Assistant Professor, Department of Medicine, University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion